Take home message {#Sec1}
=================

TAP-based decontamination regimens appear superior versus other methods at reducing incidences of overall VAP and bacteremia infections among ICU patients.Structural equation modeling of published *Pseudomonas* and *Acinetobacter* infection data enables a test of the control of gut overgrowth concept in the mediation of TAP-based decontamination.Paradoxically, both *Acinetobacter* and *Pseudomonas* bacteremia incidences are unusually high among studies of TAP.

Tweet {#Sec2}
=====

GSEM modeling of *Pseudomonas* and *Acinetobacter* gut overgrowth demonstrates complex and paradoxical relationships within SDD/SOD studies.

Introduction {#Sec3}
============

Of three broad categories of infection prevention in the ICU patient group, selective oral decontamination/selective digestive decontamination (SOD/SDD) shows superior apparent benefit towards overall infection prevention within the ICU context versus anti-septic-based and non-decontamination-based prevention methods \[[@CR1]--[@CR9]\].

The control of gut overgrowth (COGO) is one mechanism proposed to explain how SOD/SDD regimens might prevent ICU-acquired infection. In general, the antibiotics constituent within SOD/SDD regimens, such as topical polymyxin and aminoglycosides, specifically target Gram-negative bacilli including *Pseudomonas* and *Acinetobacter* bacteria whereas anti-septic- and non-decontamination-based prevention methods do not \[[@CR10]\].

The exact mechanism for how each of these methods prevents ICU-acquired infection, the basis for the apparent superiority of SOD/SDD among these methods, and even the optimal locus for decontamination, whether the gut or elsewhere, remains unclear despite \> 200 studies among patients requiring prolonged mechanical ventilation (MV) or ICU stay \[[@CR11]\]. Moreover, the relative importance of the individual SDD components, topical (TAP), enteral (EAP), and protocolized parenteral antibiotic prophylaxis (PPAP; not contained within SOD regimens), versus other methods of infection prevention and versus other contextual exposures such as length of stay and being in a trauma ICU context remains unclear. In addition, concurrency, being the concurrent mixing of study and control patients within the ICU, as typically occurs within randomized concurrent control studies, is believed to influence the results of SOD/SDD studies versus studies without concurrency (i.e., concurrent versus non-concurrent control; CC versus NCC) \[[@CR10], [@CR12]\].

The objectives here are threefold. Firstly, to recapitulate the evidence for overall ventilator-associated pneumonia (VAP) and bacteremia prevention among the three broad categories of infection prevention for which *Pseudomonas* and *Acinetobacter* infection data is available. Secondly, to develop and confront candidate models founded on COGO concepts using *Pseudomonas* and *Acinetobacter* infection data from these studies as well as studies without an intervention using GSEM modeling. Thirdly, to compare the relative impacts of the various group-level exposures and interventions on *Pseudomonas* and *Acinetobacter* gut overgrowth as latent variables within the optimal GSEM model.

Materials and methods {#Sec4}
=====================

Being an analysis of published work, ethics committee review of this study was not required.

Study selection and decant of groups {#Sec5}
------------------------------------

The literature search and study decant used here (Fig [S1](#MOESM1){ref-type="media"}; see Electronic Supplementary Material for additional ESM tables, ESM figures, and ESM references) is in six steps which is described in full in the ESM and as described previously \[[@CR13]\].

Of note, studies undertaken in the context of an ICU outbreak \[[@CR14]--[@CR16]\] were excluded. Due to the absence of eligible studies of TAP undertaken in Asia and Central and South America, together with the significant worldwide variation in both *Pseudomonas* \[[@CR17]\] and moreso *Acinetobacter*-associated VAP \[[@CR18]\], studies from these regions were excluded from this analysis. A snowballing search strategy \[[@CR19]\] using the "Related articles" function within Google Scholar was undertaken for additional studies not identified within systematic reviews.

All eligible studies were then collated, and any duplicate studies were removed and streamed into groups of patients from studies with or without an infection prevention intervention. Those studies without a study intervention provide observational groups.

The component groups were decanted from each study as either observational, control, or intervention groups. Within studies of TAP, any group receiving TAP in any formulation was regarded as an intervention group and all other groups were regarded as a control group regardless of other interventions. The control groups from studies of TAP were stratified into NCC and CC groups.

Outcomes of interest {#Sec6}
--------------------

The incidences of overall *Pseudomonas* and *Acinetobacter* VAP as well as the incidences of overall *Pseudomonas* and *Acinetobacter* bacteremia were extracted. These were each expressed as a proportion using the number of patients with prolonged (\> 24 h) stay in the ICU as the denominator. *Pseudomonas* and *Acinetobacter* gut overgrowth are latent variables as defined within the GSEM models (see below).

Exposures of interest {#Sec7}
---------------------

The following were also extracted where available: the proportion of each group receiving MV, the proportion of admissions for trauma, and the mean length of ICU stay (LOS). An anti-septic exposure included agents such as chlorhexidine, povidone-iodine, and iseganan. All anti-septic exposures were included regardless of whether the application was to the oropharynx, by tooth-brushing or by body wash.

TAP is defined here as the application of topical antibiotic (TA) prophylaxis to the oropharynx without regard to the specific TA constituents nor to concomitant EAP, being the enteral applications of TA, or PPAP. Note that SOD generally consists of only TAP whereas SDD typically involves TAP together with both EAP and PPAP. A control group of an SOD/SDD study was classified as a CC control if the group was concurrent within the same ICU at the same time as intervention group patients were receiving TAP.

Visual benchmarking {#Sec8}
-------------------

Scatter plots of the overall and *Pseudomonas* and *Acinetobacter* VAP and bacteremia incidence data were generated to facilitate a visual survey of the entire data as derived from the literature. To facilitate this visual survey, a benchmark for each outcome of interest was generated from the groups of the observational studies using the "metan" command as described in the ESM. The caterpillar plots \[[@CR20]\] illustrating the derivation of each bacteremia benchmark are shown in the supplementary material.

Structural equation modeling {#Sec9}
----------------------------

Seven candidate GSEM models were developed using *Pseudomonas* and *Acinetobacter* gut overgrowth as the central latent variables. Group exposure or not to the following factors served as binary indicator variables towards these two latent variables: non-decontamination-based prevention methods, anti-septic-based prevention methods, TAP-based prevention methods, exposure to PPAP, membership of a CC control group within a TAP intervention study, whether the majority of the group were trauma patients, whether more than 90% of patients of the group received more than 24 h of MV, and whether the mean (or median) length of ICU stay for the group was 7 days or more.

The VAP and bacteremia count data for each of *Pseudomonas* and *Acinetobacter* using the number of observed patients as the denominator served as the measurement component for the latent variables using a logit link function in each GSEM. In each model, the observations were clustered by a study identifier in order to generate a robust variance covariance matrix of the parameters of each coefficient estimate. The various exogenous variables were entered into each model without any preselection step to sequentially develop the seven candidate GSEM models using the "GSEM" command in Stata \[[@CR21]\]. The model with the lowest Akaike's information criterion (AIC) score was selected as having parsimony and optimal fit from among the seven candidate models.

Availability of data and materials {#Sec10}
----------------------------------

All data generated or analyzed during this study are included in this published article and its supplementary information files (see ESM).

Results {#Sec11}
=======

Characteristics of the studies {#Sec12}
------------------------------

Of the 214 studies identified by the search, 130 were sourced from 23 systematic reviews. Others were found during previous searches or by snowball sampling \[[@CR19]\] (Fig [S1](#MOESM1){ref-type="media"}). Most studies were published between 1990 and 2010, and most had a mean ICU LOS exceeding 7 days. A minority originated from either North American or trauma ICUs. Twenty-one studies had either no control group or more than one control or intervention group. The majority of groups from studies of infection prevention interventions had less than 150 patients per group versus more than 150 patients in the observational studies.

Among the various types of TAP regimen, either topical polymyxin or topical aminoglycoside or both were contained in every regimen except two. PPAP, being a cephalosporin in every case except two, was used within eight control groups and 29 intervention groups of TAP studies. Among TAP intervention groups, 23 used TAP alone (i.e., SOD regimens) and 29 used TAP, EAP, and PPAP in combination (i.e., SDD regimens).

Overall infection prevention effect {#Sec13}
-----------------------------------

The summary effect sizes for the three categories of interventions against overall VAP (Fig [S2 - S4](#MOESM1){ref-type="media"}) and also against overall bacteremia (Fig [S5-S7](#MOESM1){ref-type="media"}) incidence are presented as caterpillar plots. The TAP-based interventions provided greater apparent protection against VAP versus the two other intervention categories (Table [1](#Tab1){ref-type="table"}). Of note, the TAP studies which did (i.e., SDD regimens) versus did not (i.e., SOD regimens) include PPAP within the intervention demonstrated greater protection against both overall bacteremia and overall VAP (Table [1](#Tab1){ref-type="table"}). Table 1Characteristics of studiesObservational studiesInfection prevention studiesNo interventionNon-decontaminationAnti-septicTAP ± PPAP/EAPStudy characteristics Sources[Table S1](#MOESM1){ref-type="media"}[Table S2](#MOESM1){ref-type="media"}[Table S3](#MOESM1){ref-type="media"}[Table S4](#MOESM1){ref-type="media"} Number of studies^a^111451348 Origin from systematic review^b^4638738 North American ICUs^c^321063 LOS \> 7 days8837937 MV for \> 48 h for \< 90%^d^211511 Trauma ICUs^e^228214 PPAP use in the control group^f^0018 Study publication year (range)1987--20141987--20172000--20181984--2018Group characteristics Numbers of patients per control group (median; IQR)^g^279135--7077561--1619636--2178631--128Prevention effect size (odds ratio; 95% CI; number of studies) VAPNA0.73; 0.66--0.80 (45)(see [Fig S2](#MOESM1){ref-type="media"})0.89; 0.72--1.11 (10)(see [Fig S3](#MOESM1){ref-type="media"})0.38; 0.33--0.44 (37)^h^(see [Fig S4](#MOESM1){ref-type="media"}) BacteremiaNA0.99; 0.71--1.39 (6)(see [Fig S5](#MOESM1){ref-type="media"})0.72; 0.66--0.79 (10)(see [Fig S6](#MOESM1){ref-type="media"})0.69; 0.62--0.76 (33)^i^(see [Fig S7](#MOESM1){ref-type="media"})^a^Several studies had more than one control and/or intervention group. Hence, the number of groups does not equal the number of studies^b^Studies that were sourced from 16 systematic reviews (references in web-only supplementary)^c^Study originating from an ICU in Canada of the USA^d^Studies for which less than 90% of patients were reported to receive \> 48 h of MV^e^Trauma ICU arbitrarily defined as an ICU with more than 50% of admissions for trauma^f^Use of PPAP for control group patients. PPAP is protocolized parenteral antibiotic prophylaxis^g^Data is median and inter-quartile range (IQR)^h^VAP prevention effect size for studies not including versus including PPAP in the antibiotic intervention was 0.44; 0.36--0.55 (*n* = 13) and 0.34; 0.28--0.41 (*n* = 24), respectively (see Fig [S4](#MOESM1){ref-type="media"})^i^Bacteremia prevention effect size for studies not including versus including PPAP in the antibiotic intervention was 0.77; 0.68--0.88 (*n* = 10) and 0.57; 0.48--0.67 (*n* = 22), respectively (see Fig [S7](#MOESM1){ref-type="media"})

GSEM modeling {#Sec14}
-------------

Seven candidate GSEM models of the relationship between various group-level exposures on *Pseudomonas* and *Acinetobacter* gut overgrowth as latent variables were evaluated for fit and parsimony (see Table [2](#Tab2){ref-type="table"}; Fig [S8--S14](#MOESM1){ref-type="media"}). The optimal model (model 6) is shown (Fig. [1](#Fig1){ref-type="fig"}). In developing the seven candidate GSEM models, exposures to PPAP and non-decontamination interventions on *Pseudomonas* and *Acinetobacter* gut overgrowth were both associated with weak coefficients and these pathways were dropped from model 2 onwards. EAP was not a significant factor, and its introduction failed to improve the model fit (model 7, Fig [S14](#MOESM1){ref-type="media"}). Table 2Development of the GSEM modelModel 1Model 2Model 3Model 4Model 5Model 7Model 6Fig [S8](#MOESM1){ref-type="media"}Fig [S9](#MOESM1){ref-type="media"}Fig [S10](#MOESM1){ref-type="media"}Fig [S11](#MOESM1){ref-type="media"}Fig [S12](#MOESM1){ref-type="media"}Fig [S14](#MOESM1){ref-type="media"}Fig [S13](#MOESM1){ref-type="media"}95% CI**Factor**^a,b,c,d,e,f,g,h,i^**b_Ps_n*Pseudomonas*** gut overgrowth1111111Constrained**ppap**1.11\*\*0.97\*\*0.97\*\*1.00\*\*0.95\*\*0.27 to 1.61**\_cons**− 5.18\*\*\*− 5.19\*\*\*− 5.38\*\*\*− 6.00\*\*\*− 6.00\*\*\*− 6.05\*\*\*− 6.05\*\*\*− 6.6 to − 5.4**b_Ac_nAcinetobacter GO**1111111Constrained**ppap**0.60.460.480.440.47− 0.51 to 4639**\_cons**− 6.74\*\*\*− 6.74\*\*\*− 6.83\*\*\*− 7.38\*\*\*− 7.44\*\*\*− 7.47\*\*\*− 7.47\*\*\*− 8.0 to − 7.0**v_Ps_nPseudomonas** gut overgrowth0.67\*\*\*0.67\*\*\*0.71\*\*\*0.80\*\*\*0.80\*\*\*0.81\*\*\*0.81\*\*\*0.51 to 1.09**mvp90**0.55\*0.54\*0.49\*0.430.430.48\*0.49\*0.03 to 0.92**non_D**− 0.37\*− 0.58\*\*\*− 0.61\*\*\*− 0.60\*\*\*− 0.60\*\*\*− 0.54\*\*\*− 0.54\*\*\*− 0.79 to − 0.31**\_cons**− 3.63\*\*\*− 3.63\*\*\*− 3.56\*\*\*− 4.17\*\*\*− 4.17\*\*\*− 4.24\*\*\*−4.25\*\*\*− 4.7 to − 3.7**v_Ac_nAcinetobacter** gut overgrowth0.73\*\*\*0.73\*\*\*0.74\*\*\*0.83\*\*\*0.83\*\*\*0.83\*\*\*0.83\*\*\*+ 0.66 to 1.01**mvp90**0.79\*0.79\*0.730.710.690.710.7− 0.12 to 1.55**non_D**− 0.35− 0.31− 0.33− 0.27− 0.21− 0.17− 0.17− 0.56 to 0.23**\_cons**− 5.13\*\*\*− 5.13\*\*\*− 5.06\*\*\*− 5.79\*\*\*− 5.85\*\*\*− 5.88\*\*\*− 5.87\*\*\*− 6.8 to −4.9**Pseudomonas** gut overgrowth**TAP**− 0.65\*\*− 0.65\*\*− 0.67\*\*\*− 0.68\*\*\*− 0.68\*\*\*− 0.47\*− 0.57\*\*\*− 0.91 to − 0.29**a_S**− 1.34\*\*\*− 1.33\*\*\*− 1.20\*\*\*− 1.01\*\*\*− 1.00\*\*\*− 0.94\*\*\*− 0.93\*\*\*− 1.46 to − 0.46**eap**− 0.21**ppap**0.270.27**non_D**−0.33**los7**1.03\*\*\*1.03\*\*\*0.96\*\*\*0.97\*\*\*0.53 to 1.45**trauma50**0.040.030.02− 0.33 to 0.36**CC**0.56\*\*0.56\*\*0.08 to 1.10**Acinetobacter** gut overgrowth**TAP**− 0.25− 0.25− 0.27− 0.27− 0.5− 0.58− 0.43− 1.04 to 0.15**a_S**− 1.26\*− 1.27\*− 1.21\*− 1.04\*− 0.85− 0.8− 0.82− 1.83 to 0.19**eap**0.25**ppap**0.10.1**non_D**0.06**los7**1.15\*\*\*1.01\*\*\*0.99\*\*\*0.98\*\*\*0.41 to 1.54**trauma50**1.09\*\*\*1.04\*\*\*1.04\*\*\*0.47 to 1.62**CC**0.420.42− 0.22 to 1.22**Error termsvar(e.Ps_GO)**1.32\*1.32\*1.17\*\*0.76\*\*0.76\*\*0.71\*\*0.72\*\*0.36 to 1.47**var(e.Ac_GO)**2.66\*\*\*2.66\*\*\*2.56\*\*\*1.92\*\*\*1.62\*\*\*1.60\*\*\*1.60\*\*\*1.01 to 2.48**Model fit**^j^**AIC**3345.943344.153329.293274.573261.553259.13255.53***N***22202022242826**Groups (*n*)**334334334334334334334**Clusters (*n*)**213213213213213213213\**p* \< 0.05; \*\**p* \< 0.01; \*\*\**p* \< 0.001^a^v_ps_n is the count of *Pseudomonas* VAP; v_ac_n is the count of *Acinetobacter* VAP; b_ps_n is the count of *Pseudomonas* bacteremia; and b_ac_n is the count of *Acinetobacter* bacteremia^b^PPAP is the group-wide use of protocolized parenteral antibiotic prophylaxis; TAP is topical antibiotic prophylaxis; eap is enteral antibiotic prophylaxis^c^e.Ac_GO is the error term for the *Acinetobacter* gut overgrowth latent variable^d^e.Ps_GO is the error term for the *Pseudomonas* gut overgrowth latent variable^e^MVP90 is the use of mechanical ventilation by more than 90% of the group^f^LOS7 is a mean or median length of ICU stay for the group of 7 days or greater^g^Trauma ICU arbitrarily defined as an ICU for which \> 50% of admissions were for trauma^h^CC is the concurrency of control groups with an intervention group receiving TAP^i^Less than 90% of the group receiving prolonged mechanical ventilation.^j^Model fit; AIC is Akaike's information criteria. This indicates model fit taking into account the statistical goodness of fit and the number of parameters in the model. Lower values of AIC indicate a better model fit. *N* is the number of parameters in the modelFig. 1The optimal GSEM (model 6) founded on COGO concepts in relation to *Pseudomonas* and *Acinetobacter* infection data. *Pseudomonas* GO and *Acinetobacter* GO (ovals) are latent variables representing *Pseudomonas* and *Acinetobacter* gut overgrowth (GO), respectively. The variables in rectangles are binary predictor variables representing the group-level exposure to the following: a trauma ICU setting (trauma50), mean or median length of ICU stay ≥ 7 days (los7), exposure to a topical anti-septic-based prevention method (a_S), exposure to a TAP-based prevention method (tap), concurrency of a control group with a TAP intervention group (CC), exposure to a non-decontamination-based prevention method (non-D), use of mechanical ventilation for more than 90% of the group (mvp90), or exposure to PPAP (ppap). The circles contain error terms. The three-part boxes represent the count data for *Pseudomonas* and *Acinetobacter* VAP (v_ps_n, v_ac_n) and bacteremia (b_ps_n, b_ac_n). These counts are logit transformed with the total number of patients in each group as the denominator using the logit link function in the generalized model of the GSEM. Note that EAP use is confounded by PPAP use and that EAP use when separately entered into model 7 (ESM Fig [S14](#MOESM1){ref-type="media"}) was non-significant

A mean ICU LOS ≥ 7 days was strongly correlated with both *Pseudomonas* gut overgrowth (+ 0.97; 0.53 to 1.45) and *Acinetobacter* gut overgrowth (+ 0.98; 0.41 to 1.54). Exposure to anti-septic interventions was associated with a stronger negative coefficient (− 0.93; − 1.46 to − 0.46) than was exposure to TAP (− 0.57; − 0.91 to − 0.29) towards *Pseudomonas* gut overgrowth but neither exposure was significant towards *Acinetobacter* gut overgrowth. Membership of a control group concurrent to a TAP intervention group was associated with a significant positive coefficient (+ 0.56; 0.08 to 1.10) towards *Pseudomonas* gut overgrowth. PPAP use was a strong positive correlate of *Pseudomonas* bacteremia (+ 0.95; 0.27 to 1.61).

VAP and bacteremia count data {#Sec15}
-----------------------------

The *Pseudomonas* and *Acinetobacter* VAP and bacteremia infection data is presented as percentages (Fig. [2](#Fig2){ref-type="fig"}) and as tallied counts (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). There were a small number of very large studies with a mean LOS \< 7 days and without VAP data. Hence, the tallied counts limited to studies with mean length of stay ≥ 7 days are also shown (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Fig. 2Scatter plots of *Pseudomonas* (right) and *Acinetobacter* (left) VAP (top) and bacteremia (bottom) incidence proportions for the component groups from all studies versus benchmarks derived from observational (Ob) groups. The control and intervention groups are stratified by studies of either non-decontamination (Non-D) methods, anti-septic-based methods (A_s), or antibiotic (Ab, TAP)-based methods. The summary mean and summary 95% confidence intervals are displayed for each category. The derivation of these confidence intervals by random effects methods is displayed in caterpillar plots (Fig [S15-S22](#MOESM1){ref-type="media"}) in the ESM for the bacteremia data. Note that the *x* axis is a logit scale. Control and intervention groups exposed to PPAP within TAP studies are indicated as solid symbols versus not exposed (open symbols)Table 3VAP count dataObservational studiesInfection prevention studiesNo interventionNon-decAnti-septicTAP ± PPAPExcluding groups with LOS \< 7 days*Acinetobacter*  CC or observational groups586/37026^a,b^1.6% (67)30/2620^a^1.1% (25)4/780^a^0.5% (5)67/1521^a^4.4% (25)  Intervention groups34/2429^b^1.4% (24)8/786^b^1.0% (5)41/1721^b^2.4% (26)*Pseudomonas*  CC or observational groups2217/60131^c,\ d^3.7% (81)200/4288^c^4.7% (38)27/914^c^3.0% (8)179/2161^c^8.3% (34)  Intervention groups167/4169^d^4.0% (37)24/1027^d^2.3% (8)106/3193^d^3.3% (37)*Non-dec* non-decontamination studies, *TAP* topical antibiotic prophylaxis, *PPAP* protocolized parenteral antibiotic prophylaxis.^a^The counts of *Acinetobacter* VAP among the three categories of control groups and the category of observation groups among studies after excluding those with length of stay \< 7 days differed significantly (*p* \< 0.001; Fisher's exact test)^b^The counts of *Acinetobacter* VAP among the three categories of intervention groups and the category of observation groups among studies after excluding those with length of stay \< 7 days differed significantly (*p* = 0.038; Fisher's exact test)^c^The counts of *Pseudomonas* VAP among the three categories of control groups and the category of observation groups among studies after excluding those with length of stay \< 7 days differed significantly (*p* \< 0.001; Fisher's exact test)^d^The counts of *Pseudomonas* VAP among the three categories of intervention groups and the category of observation groups among studies after excluding those with length of stay \< 7 days differed marginally (*p* = 0.05; Fisher's exact test)Table 4Bacteremia count dataObservational studiesInfection prevention studiesNo interventionNon-decAnti-septicTAP ± PPAPAll groups*Acinetobacter*  CC or observational groups203/1893380.11% (20)1/5530.18% (2)17/391620.04% (8)15/18600.8% (13)  Intervention groups1/5260.19% (2)7/570090.01% (8)15/13290^a^0.11% (18)*Pseudomonas*  CC or observational groups567/1922030.30% (27)2/5530.36% (2)23/391620.06% (8)63/52801.2% (16)  Intervention groups3/5260.57% (2)52/591170.09% (9)139/235430.59% (25)Excluding groups with LOS \< 7 days*Acinetobacter*  CC or observational groups37/12913^b,c^0.29% (11)0/200^b^0% (1)0/308^b^0% (3)14/904^b^1.5% (11)  Intervention groups1/199^c^0.5% (1)1/305^c^0.33% (3)11/1256^c^0.88% (14)*Pseudomonas*  CC or observational groups111/14453^d,e^0.77% (16)0/200^d^0% (1)0/308^d^0.0% (3)63/5249^d^1.2% (15)  Intervention groups2/199^e^1.0% (1)17/2413^e^0.7% (4)94/12531^e,f^0.75% (22)*Non-dec* non-decontamination studies, *TAP* topical antibiotic prophylaxis, *PPAP* protocolized parenteral antibiotic prophylaxis.^a^Among intervention groups of TAP-based prevention studies, the count of *Acinetobacter* bacteremias was 12/6609 (0.18%; 13 studies) versus 3/6681 (0.04%; 4 studies) for those using versus not including PPAP in the intervention (*p* = 0.02; Fisher's exact test)^b^The counts of *Acinetobacter* bacteremias among the three categories of control groups and the category of observation groups among studies after excluding those with length of stay \< 7 days differed significantly (*p* \< 0.001; Fisher's exact test)^c^The counts of *Acinetobacter* bacteremias among the three categories of intervention groups and the category of observation groups among studies after excluding those with length of stay \< 7 days differed significantly (*p* = 0.012; Fisher's exact test)^d^The counts of *Pseudomonas* bacteremias among the three categories of control groups and the category of observation groups among studies after excluding those with length of stay \< 7 days differed significantly (*p* = 0.010; Fisher's exact test)^e^The counts of *Pseudomonas* bacteremias among the three categories of intervention groups and the category of observation groups among studies after excluding those with length of stay \< 7 days were not significantly different (*p* = 0.90; Fisher's exact test)^f^Among intervention groups of TAP-based prevention studies excluding those with a LOS less than 7 days, the count of *Pseudomonas* bacteremias was 53/5908 (0.9%; 16 studies) versus 41/6623 (0.62%; 6 studies) for those using versus not including PPAP in the intervention (*p* = 0.07; Fisher's exact test)

Whether as incidence percentages within individual studies as noted in the caterpillar plots and scatter plots or as counts tallied across all studies, the incidences of infection were generally higher among the control and intervention groups of TAP studies with respect to both *Pseudomonas* and *Acinetobacter* (Fig. [2](#Fig2){ref-type="fig"}). There was one exception to this in that the *Pseudomonas* VAP incidences among TAP intervention groups were mostly below the *Pseudomonas* VAP benchmark as was the *Pseudomonas* VAP tallied count among groups with LOS \< 7 days excluded (*p* = 0.05; Table [3](#Tab3){ref-type="table"}).

Of note, among the TAP intervention groups, the *Acinetobacter* bacteremia tallied count among groups also exposed to PPAP (12/6609; 0.18%) was higher versus the tallied count among those exposed to TAP alone (3/6681; 0.04%; *p* = 0.02, Fisher's exact test). Likewise, for *Pseudomonas* bacteremia among the TAP intervention groups after excluding those groups with LOS \< 7 days (Table [4](#Tab4){ref-type="table"}), there was a marginally higher tallied count among groups also exposed to PPAP (53/5908; 0.9%) versus the tallied count among those exposed to TAP alone (41/6623; 0.62%; *p* = 0.07, Fisher's exact test).

Discussion {#Sec16}
==========

Generally accepted risk factors towards the acquisition of Gram-negative bacilli in the ICU include LOS \> 7 days, exposure to invasive devices such as MV, and exposure to antibiotics together with acquisition by cross infection within the ICU environment \[[@CR10]\]. A GSEM model founded on COGO concepts is used to evaluate these risk factors versus other group-level exposures. This GSEM model enables the component groups of studies of the various infection prevention methods to be considered as a natural experiment with various group-wide exposures among over two hundred ICU populations in the literature. This enables a novel perspective on the COGO concept that would not be possible within any one study examined in isolation nor within several studies examined collectively as within a systematic review \[[@CR22]\].

The data used here to confront the COGO model is drawn mostly from studies located in systematic reviews. The extracted data is provided in sufficient detail in the ESM to enable replication of the analysis. In this regard, the summary effect sizes here for each of the three broad categories of TAP, anti-septic, and non-decontamination methods, against both overall VAP and against overall bacteremia, are similar to prior published estimates \[[@CR1]--[@CR10]\]. As has previously been noted, TAP (moreso when in combination with PPAP \[[@CR23]\]) appears to have the strongest prevention effect against both overall VAP and against overall bacteremia.

In confronting the COGO model with the *Pseudomonas* and *Acinetobacter* infection data, the COGO model is robust with several factors remaining consistent over the evolution through seven candidate versions of the GSEM. There are several expected observations. Length of stay and admission to a trauma ICU are strong positive factors, and non-decontamination interventions appear not to mediate significant effects on either *Pseudomonas* gut overgrowth or *Acinetobacter* gut overgrowth. TAP exposure is associated with a negative coefficient towards *Pseudomonas* gut overgrowth, albeit weaker than that associated with anti-septic interventions. These negative coefficients in association with TAP and anti-septic exposures towards *Pseudomonas* gut overgrowth reflect the generally lower *Pseudomonas* VAP among the intervention groups of these studies.

On the other hand, the various components of the SOD/SDD regimens, TAP, EAP, and PPAP, have mixed effects within the GSEM models. Neither TAP nor EAP has negative coefficients towards *Acinetobacter* gut overgrowth. This is surprising as in nearly all instances these contain polymyxin and/or an aminoglycoside. Moreover, PPAP is associated with a strong positive correlation with *Pseudomonas* bacteremia.

Finally, patient groups exposed to the full SDD regimen (i.e., all of TAP, EAP, and PPAP) have *Pseudomonas* and *Acinetobacter* bacteremia incidences that are either higher than or else not lower than patient groups receiving TAP alone. This is possibly not paradoxical as antibiotics used for PPAP typically lack activity against *Pseudomonas* and *Acinetobacter.* In this regard, the cumulative days of exposure to antibiotics without activity against *Pseudomonas* have been reported as being a risk factor for acquiring *P. aeruginosa* and *Acinetobacter* in the ICU \[[@CR24]--[@CR26]\]. Moreover, concomitant systemic antibiotic therapy fails to prevent the acquisition of respiratory tract colonization with Gram-negative bacteria \[[@CR27]\] and more than triples the risk of subsequent infection among ICU patients receiving an enteral decolonization regimen with gentamicin against KPC-producing *Klebsiella pneumonia* \[[@CR28]\] and CRE-producing *Acinetobacter* \[[@CR29]\].

The exact relationship between gut colonization, PPAP use, and subsequent bacteremia remains controversial amid conflicting reports that PPAP use may or may not be important for some Gram-negative bacteremias versus others \[[@CR30]--[@CR33]\]. In studying the relative prevention effects of SDD versus SOD each versus standard care in the prevention of Gram-negative bacteremias (i.e., not limited to *Pseudomonas* bacteremia), the majority of bacteremias occur after 4 days in the ICU (the typical duration of PPAP) and indeed the daily risk peaks after day 30 \[[@CR11], [@CR31]\]. Moreover, among patients receiving SDD or SOD, *Pseudomonas* accounts for one third of GN bacteremia episodes with most episodes not preceded by enteral colonization.

Defining the separate effects of EAP, TAP, and PPAP on the *Acinetobacter* and *Pseudomonas* bacteremia incidences is difficult as these exposures are confounded with each other among the multiple SDD/SOD regimens under investigation in the different studies. Also, the duration of the application of the regimens and the duration of follow up varied among the studies. In this regard, a non-significant increase in hospital-acquired infections post discharge from the ICU as great as 50% was noted in a small SDD sub-study \[[@CR34]\].

In critical care research, SEM is emerging as a method to model the relationships among multiple simultaneously observed variables in order to provide a quantitative test of any theoretical model proposed within the literature \[[@CR35]\]. The use of latent variables within the model enables the ability to test the validity of concepts that can only be indirectly quantified through their inferred relationship to observed variables \[[@CR36]\]. GSEM allows generalized linear response functions in addition to the linear response functions allowed by SEM.

Limitations {#Sec17}
-----------

There are five key limitations to this analysis, the first being that this analysis is a group-level modeling of two latent variables, *Pseudomonas* gut overgrowth and *Acinetobacter* gut overgrowth, within a GSEM founded on the COGO construct. These latent variables and the coefficients derived in the GSEM are indicative and intended for internal reference only. They have no counterpart at the level of any one patient or study and cannot be directly measured. There was no ability nor purpose to adjust for the underlying patient-level risk. There was considerable heterogeneity in the interventions, populations, and study designs among the studies here as the inclusion criteria for the various studies have been intentionally broadly specified. In this regard, a strength of the analysis is that the heterogeneity among the studies here generally resembles that expected among ICU populations to which these interventions might be targeted.

The second limitation is that the analysis is inherently observational. Only a limited number of key group-level factors were entered into the GSEM models. Moreover, the GSEM modeling is deliberately simplistic with exposures entered as only binary variables and without the use of interaction terms. In reality, the relationships between exposures and outcomes will likely be complex and exposure interactions could have great importance.

Thirdly, the analysis is likely underpowered to examine the *Acinetobacter* infection data, being a relatively rare end point. Likewise, the incidences of resistant infections with *Acinetobacter* and *Pseudomonas* are of great interest. However, examination of the incidence of these resistant infections is difficult as these end points are generally uncommon or rare and have been inconsistently reported among these studies here.

Fourthly, only those studies for which *Pseudomonas* and *Acinetobacter* infection data were available were able to be included in this analysis. However, the effect of the interventions on overall VAP and bacteremia incidences among the studies included here (Fig [S2-S7](#MOESM1){ref-type="media"}) resembles that in the broader literature.

Finally, it should be noted that the various interventions among the studies here targeted a range of sites which may or may not have included the oropharynx and gastrointestinal tract. In this regard, it is surprising that the TAP and EAP interventions, which most directly target the oropharynx and gastrointestinal tract, had weaker effects than did anti-septic interventions, several of which, such as chlorhexidine body washes, target other sites.

Can the paradoxical findings of the GSEM model be reconciled with the apparent superior summary prevention effects of TAP against VAP and bacteremia? TAP exposure and control group concurrency have associations with *Pseudomonas* gut overgrowth that are each similar in size but contrary in direction to each other. In this regard, the incidences of overall VAP, overall bacteremia and also mortality \[[@CR37]\] among the concurrent control groups within studies of SOD/SDD are as much as ten percentage points higher than the repsective incidences of these end points among the control groups within studies of equivalent ICU populations. This higher overall VAP incidence can partly be accounted for by incidences of VAP with specific bacteria such as *Acinetobacter* \[[@CR38]\], *Pseudomonas* \[[@CR39]\], and *Staphylococcus aureus* \[[@CR40]\] being each 3 to 5 percentage points higher among CC (but not NCC) control groups and these incidences are generally each up to 2 percentage points higher for the intervention groups of SOD/SDD studies*.*

Likewise, the higher overall bacteremia incidence can partly be accounted for by noting that the incidences of bacteremia with specific bacteria are generally 1 to 4 percentage points higher among CC (but not NCC) control groups. Even among intervention groups, these bacteremia incidences may on average be up to 3 percentage points higher for *Acinetobacter* (Fig. [2](#Fig2){ref-type="fig"}), *Pseudomonas* (Fig. [2](#Fig2){ref-type="fig"}) \[[@CR41]\], *Staphylococcus aureus* \[[@CR42]\], *Enterococci* \[[@CR43]\], and *coagulase-negative Staphylococci* \[[@CR44]\]*.*

In each case, the increased incidence within control groups of CC design studies of topical antibiotics remains apparent in meta-regression models adjusting for other recognized associations. The influence of topical placebo use, concurrent colonization with *Candida*, and other influences may also have influences in this process \[[@CR45]--[@CR47]\].

Hence, reconciling the findings of the GSEM model founded on COGO concepts on the one hand, with the apparent superior summary prevention effects of TAP against VAP and bacteremia, on the other, is possible by noting that the incidences of VAP and bacteremia are generally higher among CC (but not NCC) control groups of studies of TAP. These higher incidences within CC (but not NCC) control groups of studies of TAP remain to be explained.

Conclusion {#Sec18}
==========

TAP-based decontamination regimens appear superior versus other methods at reducing incidences of overall VAP and bacteremia infections among ICU patients. GSEM modeling of *Pseudomonas* gut overgrowth and *Acinetobacter* gut overgrowth as latent variables versus group-level exposures demonstrates complex and paradoxical relationships which would not be apparent in any single study examined in isolation nor within a summary effect of the collective studies as derived by a conventional meta-analysis. Paradoxically, despite the superior apparent infection prevention effect observed among studies of TAP, *Acinetobacter* bacteremia incidences are unusually high among studies of TAP. Moreover, in TAP-exposed groups, the additional exposure to PPAP is associated with higher *Acinetobacter* bacteremia incidences and PPAP is a strongly positive factor towards *Pseudomonas* bacteremia in the GSEM model. In the light of these paradoxical findings, crucially, is TAP safe within the ICU context \[[@CR13]\]?
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COGO

:   Control of gut overgrowth

EAP

:   Enteral antibiotic prophylaxis
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:   Generalized structural equation models
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MV
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NCC

:   Non-concurrent control

CC

:   Concurrent control

SOD/SDD

:   Selective oral decontamination/selective digestive decontamination

TAP

:   Topical antibiotic prophylaxis
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